Biofrontera Inc.
BFRI
$0.86
$0.0121.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.00M | 37.32M | 35.36M | 35.24M | 33.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.00M | 37.32M | 35.36M | 35.24M | 33.25M |
| Cost of Revenue | 17.76M | 18.61M | 18.70M | 18.42M | 16.96M |
| Gross Profit | 20.24M | 18.72M | 16.66M | 16.83M | 16.29M |
| SG&A Expenses | 33.25M | 33.84M | 34.68M | 34.95M | 38.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.29M | 54.53M | 54.72M | 54.07M | 55.50M |
| Operating Income | -16.29M | -17.21M | -19.36M | -18.82M | -22.24M |
| Income Before Tax | -11.51M | -17.74M | -12.82M | -13.49M | -23.08M |
| Income Tax Expenses | 19.00K | 21.00K | 18.00K | 16.00K | 10.00K |
| Earnings from Continuing Operations | -11.53 | -17.76 | -12.84 | -13.51 | -23.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.53M | -17.76M | -12.84M | -13.51M | -23.09M |
| EBIT | -16.29M | -17.21M | -19.36M | -18.82M | -22.24M |
| EBITDA | -15.97M | -16.79M | -18.85M | -18.31M | -21.74M |
| EPS Basic | -1.69 | -4.10 | -2.27 | -5.92 | -13.10 |
| Normalized Basic EPS | -1.18 | -2.63 | -3.32 | -4.51 | -8.22 |
| EPS Diluted | -1.88 | -4.28 | -2.27 | -5.92 | -13.10 |
| Normalized Diluted EPS | -1.18 | -2.63 | -3.32 | -4.51 | -8.22 |
| Average Basic Shares Outstanding | 27.31M | 22.06M | 16.63M | 12.22M | 8.49M |
| Average Diluted Shares Outstanding | 27.31M | 22.06M | 16.63M | 12.22M | 8.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |